BioSpace News Archive

Business

Mustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts

The facility is expected to be operational for the production of personalized CAR T therapies in 2018.

October 30, 2017

·

4 min read

Policy

Mersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2b

This is the second IND clearance from Mersana’s novel dolaflexin ADC platform within the past year.

October 30, 2017

·

4 min read

Deals

Aviragen Therapeutics and Vaxart Enter into Merger Agreement

The merger will result in a combined company, Vaxart, focused on developing orally-delivered therapeutics and prophylactics to address a variety of viral infections.

October 30, 2017

·

11 min read

BioCanCell Announces Exploration of Funding Round Conditioned on a Going Private Transaction and Business Development Update

The investors have informed BioCanCell that the execution of the Private Investment is dependent on BioCanCell’s becoming a private company.

October 30, 2017

·

4 min read

Policy

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome and Dravet Syndrome

GW has received Rare Pediatric Disease and Orphan Drug Designations from the FDA for Epidiolex in the treatment of both LGS and Dravet syndrome.

October 30, 2017

·

6 min read

Drug Development

Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient With Severe and Symptomatic Anemia

The patient received the investigational agent through single-patient compassionate access.

October 30, 2017

·

8 min read

Novartis Could Still Spin Off Alcon, But Not Befor

Drug Development

Novartis PARADIGMS Data Show Children And Adolescents With MS Had an 82% Lower Relapse Rate With Gilenya Vs. Interferon Beta-1a

Treatment with oral Gilenya resulted in an 82% reduction in the rate of relapses (annualized relapse rate) over a period of up to two years.

October 30, 2017

·

13 min read

Deals

Ablynx Closes $200M IPO in the United States

The net proceeds are estimated at $182.3 million.

October 30, 2017

·

7 min read

Surgical Science Release: Lapsim Essence, A VR Simulator Offered As A Subscription Service, Now Ready for Delivery

Virtual reality simulation has shown to deliver an effective and patient‐safe route to technical competence in the operating room.

October 30, 2017

·

1 min read

Drug Development

argenx Launches Phase I trial With Subcutaneous Formulation of ARGX-113

The first subject has been dosed in the Phase I clinical trial.

October 30, 2017

·

5 min read